TWI331032B - - Google Patents
Download PDFInfo
- Publication number
- TWI331032B TWI331032B TW091109304A TW91109304A TWI331032B TW I331032 B TWI331032 B TW I331032B TW 091109304 A TW091109304 A TW 091109304A TW 91109304 A TW91109304 A TW 91109304A TW I331032 B TWI331032 B TW I331032B
- Authority
- TW
- Taiwan
- Prior art keywords
- calcium
- agent
- weight
- containing tissue
- bone
- Prior art date
Links
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 132
- 239000011575 calcium Substances 0.000 claims description 131
- 229910052791 calcium Inorganic materials 0.000 claims description 131
- 239000003795 chemical substances by application Substances 0.000 claims description 92
- 230000000694 effects Effects 0.000 claims description 68
- 239000000126 substance Substances 0.000 claims description 52
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 claims description 30
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 claims description 29
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 claims description 29
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 claims description 29
- 229940025878 hesperidin Drugs 0.000 claims description 29
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 claims description 29
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 29
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 claims description 29
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 28
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 claims description 28
- 238000002360 preparation method Methods 0.000 claims description 24
- 230000002708 enhancing effect Effects 0.000 claims description 23
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 claims description 23
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 22
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 15
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 15
- 235000013305 food Nutrition 0.000 claims description 15
- 235000005875 quercetin Nutrition 0.000 claims description 15
- 229960001285 quercetin Drugs 0.000 claims description 15
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 claims description 14
- 235000008777 kaempferol Nutrition 0.000 claims description 14
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 claims description 14
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims description 13
- 150000002515 isoflavone derivatives Chemical class 0.000 claims description 13
- 235000008696 isoflavones Nutrition 0.000 claims description 13
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 12
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 11
- 239000011707 mineral Substances 0.000 claims description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- 229930006000 Sucrose Natural products 0.000 claims description 9
- 229920001542 oligosaccharide Polymers 0.000 claims description 9
- 239000005720 sucrose Substances 0.000 claims description 9
- 229940088594 vitamin Drugs 0.000 claims description 9
- 229930003231 vitamin Natural products 0.000 claims description 9
- 235000013343 vitamin Nutrition 0.000 claims description 9
- 239000011782 vitamin Substances 0.000 claims description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 8
- 229930003949 flavanone Natural products 0.000 claims description 8
- 235000011981 flavanones Nutrition 0.000 claims description 8
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 claims description 8
- 235000011957 flavonols Nutrition 0.000 claims description 8
- 235000010208 anthocyanin Nutrition 0.000 claims description 7
- 239000004410 anthocyanin Substances 0.000 claims description 7
- 229930002877 anthocyanin Natural products 0.000 claims description 7
- 150000004636 anthocyanins Chemical class 0.000 claims description 7
- 150000002482 oligosaccharides Chemical class 0.000 claims description 7
- 229940043430 calcium compound Drugs 0.000 claims description 6
- 150000001674 calcium compounds Chemical class 0.000 claims description 6
- 239000002211 L-ascorbic acid Substances 0.000 claims description 5
- 235000000069 L-ascorbic acid Nutrition 0.000 claims description 5
- 229960005070 ascorbic acid Drugs 0.000 claims description 5
- 150000002208 flavanones Chemical class 0.000 claims description 5
- 150000007946 flavonol Chemical class 0.000 claims description 5
- 229930182470 glycoside Natural products 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 5
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 4
- ZONYXWQDUYMKFB-UHFFFAOYSA-N SJ000286395 Natural products O1C2=CC=CC=C2C(=O)CC1C1=CC=CC=C1 ZONYXWQDUYMKFB-UHFFFAOYSA-N 0.000 claims description 4
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 4
- 229930003316 Vitamin D Natural products 0.000 claims description 4
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 4
- 239000005018 casein Substances 0.000 claims description 4
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical group NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 4
- 235000021240 caseins Nutrition 0.000 claims description 4
- 150000002338 glycosides Chemical class 0.000 claims description 4
- 150000002681 magnesium compounds Chemical class 0.000 claims description 4
- 239000011574 phosphorus Substances 0.000 claims description 4
- 229910052698 phosphorus Inorganic materials 0.000 claims description 4
- 235000019166 vitamin D Nutrition 0.000 claims description 4
- 239000011710 vitamin D Substances 0.000 claims description 4
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 4
- 229940046008 vitamin d Drugs 0.000 claims description 4
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 4
- 235000010469 Glycine max Nutrition 0.000 claims description 3
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 claims description 3
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 claims description 3
- 235000008714 apigenin Nutrition 0.000 claims description 3
- 229940117893 apigenin Drugs 0.000 claims description 3
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims description 3
- 235000005487 catechin Nutrition 0.000 claims description 3
- 229950001002 cianidanol Drugs 0.000 claims description 3
- 235000013402 health food Nutrition 0.000 claims description 3
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 claims description 2
- 244000068988 Glycine max Species 0.000 claims description 2
- 229930003448 Vitamin K Natural products 0.000 claims description 2
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 2
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 claims description 2
- 229940117954 naringenin Drugs 0.000 claims description 2
- 235000007625 naringenin Nutrition 0.000 claims description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 235000003687 soy isoflavones Nutrition 0.000 claims description 2
- 235000019168 vitamin K Nutrition 0.000 claims description 2
- 239000011712 vitamin K Substances 0.000 claims description 2
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 2
- 229940046010 vitamin k Drugs 0.000 claims description 2
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims 1
- 125000003147 glycosyl group Chemical group 0.000 claims 1
- 229960005069 calcium Drugs 0.000 description 121
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 81
- 210000000988 bone and bone Anatomy 0.000 description 58
- 210000001519 tissue Anatomy 0.000 description 56
- 210000004027 cell Anatomy 0.000 description 31
- 230000008021 deposition Effects 0.000 description 27
- 230000002079 cooperative effect Effects 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- 239000002609 medium Substances 0.000 description 23
- 239000000523 sample Substances 0.000 description 23
- SFBODOKJTYAUCM-UHFFFAOYSA-N Ipriflavone Chemical compound C=1C(OC(C)C)=CC=C(C2=O)C=1OC=C2C1=CC=CC=C1 SFBODOKJTYAUCM-UHFFFAOYSA-N 0.000 description 22
- 229960005431 ipriflavone Drugs 0.000 description 22
- 238000012360 testing method Methods 0.000 description 20
- -1 bisphosphonate Chemical class 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 18
- 229930003935 flavonoid Natural products 0.000 description 17
- 235000017173 flavonoids Nutrition 0.000 description 17
- 238000000034 method Methods 0.000 description 17
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 16
- 150000002215 flavonoids Chemical class 0.000 description 16
- 208000001132 Osteoporosis Diseases 0.000 description 15
- 239000003513 alkali Substances 0.000 description 15
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 14
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 13
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 239000003814 drug Substances 0.000 description 12
- 239000000843 powder Substances 0.000 description 12
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 11
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 11
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 11
- 235000005493 rutin Nutrition 0.000 description 11
- 229960004555 rutoside Drugs 0.000 description 11
- 210000000515 tooth Anatomy 0.000 description 11
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 10
- 210000001694 thigh bone Anatomy 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 9
- 150000002894 organic compounds Chemical class 0.000 description 9
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 9
- 210000002303 tibia Anatomy 0.000 description 9
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 8
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 8
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 8
- 229940088597 hormone Drugs 0.000 description 8
- 239000005556 hormone Substances 0.000 description 8
- 239000013642 negative control Substances 0.000 description 8
- 230000002265 prevention Effects 0.000 description 8
- 238000007639 printing Methods 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- 229960000905 indomethacin Drugs 0.000 description 7
- 235000010755 mineral Nutrition 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 7
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 7
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 6
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- 206010036790 Productive cough Diseases 0.000 description 6
- 239000001110 calcium chloride Substances 0.000 description 6
- 229910001628 calcium chloride Inorganic materials 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000011164 ossification Effects 0.000 description 6
- 210000003802 sputum Anatomy 0.000 description 6
- 208000024794 sputum Diseases 0.000 description 6
- YEDFEBOUHSBQBT-UHFFFAOYSA-N 2,3-dihydroflavon-3-ol Chemical class O1C2=CC=CC=C2C(=O)C(O)C1C1=CC=CC=C1 YEDFEBOUHSBQBT-UHFFFAOYSA-N 0.000 description 5
- 208000006386 Bone Resorption Diseases 0.000 description 5
- 230000024279 bone resorption Effects 0.000 description 5
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 5
- 239000001527 calcium lactate Substances 0.000 description 5
- 235000011086 calcium lactate Nutrition 0.000 description 5
- 229960002401 calcium lactate Drugs 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 235000015872 dietary supplement Nutrition 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 229910001629 magnesium chloride Inorganic materials 0.000 description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
- 239000006072 paste Substances 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 4
- 244000215068 Acacia senegal Species 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 229920000084 Gum arabic Polymers 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000000205 acacia gum Substances 0.000 description 4
- 235000010489 acacia gum Nutrition 0.000 description 4
- 229930014669 anthocyanidin Natural products 0.000 description 4
- 235000008758 anthocyanidins Nutrition 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 229940074360 caffeic acid Drugs 0.000 description 4
- 235000004883 caffeic acid Nutrition 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 4
- 239000003172 expectorant agent Substances 0.000 description 4
- 230000003419 expectorant effect Effects 0.000 description 4
- 229940074391 gallic acid Drugs 0.000 description 4
- 235000004515 gallic acid Nutrition 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- VGEREEWJJVICBM-UHFFFAOYSA-N phloretin Chemical compound C1=CC(O)=CC=C1CCC(=O)C1=C(O)C=C(O)C=C1O VGEREEWJJVICBM-UHFFFAOYSA-N 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 235000007586 terpenes Nutrition 0.000 description 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 4
- JKYKXTRKURYNGW-UHFFFAOYSA-N 3,4-dihydroxy-9,10-dioxo-9,10-dihydroanthracene-2-sulfonic acid Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C(O)=C(O)C(S(O)(=O)=O)=C2 JKYKXTRKURYNGW-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 208000010392 Bone Fractures Diseases 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 241000218645 Cedrus Species 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 3
- 229960003529 diazepam Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 150000002207 flavanone derivatives Chemical class 0.000 description 3
- 150000002216 flavonol derivatives Chemical class 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- NWKFECICNXDNOQ-UHFFFAOYSA-N flavylium Chemical compound C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=[O+]1 NWKFECICNXDNOQ-UHFFFAOYSA-N 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 235000003642 hunger Nutrition 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000000606 toothpaste Substances 0.000 description 3
- 229940034610 toothpaste Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- JPFCOVZKLAXXOE-XBNSMERZSA-N (3r)-2-(3,5-dihydroxy-4-methoxyphenyl)-8-[(2r,3r,4r)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2h-chromen-4-yl]-3,4-dihydro-2h-chromene-3,5,7-triol Chemical compound C1=C(O)C(OC)=C(O)C=C1C1[C@H](O)CC(C(O)=CC(O)=C2[C@H]3C4=C(O)C=C(O)C=C4O[C@@H]([C@@H]3O)C=3C=CC(O)=CC=3)=C2O1 JPFCOVZKLAXXOE-XBNSMERZSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- ZWTDXYUDJYDHJR-UHFFFAOYSA-N (E)-1-(2,4-dihydroxyphenyl)-3-(2,4-dihydroxyphenyl)-2-propen-1-one Natural products OC1=CC(O)=CC=C1C=CC(=O)C1=CC=C(O)C=C1O ZWTDXYUDJYDHJR-UHFFFAOYSA-N 0.000 description 2
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- HSHNITRMYYLLCV-UHFFFAOYSA-N 4-methylumbelliferone Chemical compound C1=C(O)C=CC2=C1OC(=O)C=C2C HSHNITRMYYLLCV-UHFFFAOYSA-N 0.000 description 2
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 2
- 229940122361 Bisphosphonate Drugs 0.000 description 2
- 208000020084 Bone disease Diseases 0.000 description 2
- 206010065687 Bone loss Diseases 0.000 description 2
- 102000055006 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- 206010060891 General symptom Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 229930182821 L-proline Natural products 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- YQHMWTPYORBCMF-UHFFFAOYSA-N Naringenin chalcone Natural products C1=CC(O)=CC=C1C=CC(=O)C1=C(O)C=C(O)C=C1O YQHMWTPYORBCMF-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 229920001991 Proanthocyanidin Polymers 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 238000002306 biochemical method Methods 0.000 description 2
- 150000004663 bisphosphonates Chemical class 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 2
- 239000001354 calcium citrate Substances 0.000 description 2
- 229960004256 calcium citrate Drugs 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 230000003913 calcium metabolism Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960004106 citric acid Drugs 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000007598 dipping method Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 238000007046 ethoxylation reaction Methods 0.000 description 2
- 230000006203 ethylation Effects 0.000 description 2
- 238000006200 ethylation reaction Methods 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 239000001685 glycyrrhizic acid Substances 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 235000001497 healthy food Nutrition 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 101150054634 melk gene Proteins 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229960004452 methionine Drugs 0.000 description 2
- 238000006198 methoxylation reaction Methods 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 229930019673 naringin Natural products 0.000 description 2
- 229940052490 naringin Drugs 0.000 description 2
- 229940097496 nasal spray Drugs 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
- 208000028169 periodontal disease Diseases 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 229960002429 proline Drugs 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229950006451 sorbitan laurate Drugs 0.000 description 2
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000000021 stimulant Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 230000019635 sulfation Effects 0.000 description 2
- 238000005670 sulfation reaction Methods 0.000 description 2
- 229960000278 theophylline Drugs 0.000 description 2
- 239000005495 thyroid hormone Substances 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 235000013337 tricalcium citrate Nutrition 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 235000012141 vanillin Nutrition 0.000 description 2
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 2
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- OEANUJAFZLQYOD-CXAZCLJRSA-N (2r,3s,4r,5r,6r)-6-[(2r,3r,4r,5r,6r)-5-acetamido-3-hydroxy-2-(hydroxymethyl)-6-methoxyoxan-4-yl]oxy-4,5-dihydroxy-3-methoxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](OC)O[C@H](CO)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](OC)[C@H](C(O)=O)O1 OEANUJAFZLQYOD-CXAZCLJRSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- KKMOSYLWYLMHAL-UHFFFAOYSA-N 2-bromo-6-nitroaniline Chemical compound NC1=C(Br)C=CC=C1[N+]([O-])=O KKMOSYLWYLMHAL-UHFFFAOYSA-N 0.000 description 1
- CPBJMKMKNCRKQB-UHFFFAOYSA-N 3,3-bis(4-hydroxy-3-methylphenyl)-2-benzofuran-1-one Chemical compound C1=C(O)C(C)=CC(C2(C3=CC=CC=C3C(=O)O2)C=2C=C(C)C(O)=CC=2)=C1 CPBJMKMKNCRKQB-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- ZUGAOYSWHHGDJY-UHFFFAOYSA-K 5-hydroxy-2,8,9-trioxa-1-aluminabicyclo[3.3.2]decane-3,7,10-trione Chemical compound [Al+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O ZUGAOYSWHHGDJY-UHFFFAOYSA-K 0.000 description 1
- 244000235603 Acacia catechu Species 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 235000006226 Areca catechu Nutrition 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- OPSXJNAGCGVGOG-DKWTVANSSA-L Calcium L-aspartate Chemical compound [Ca+2].[O-]C(=O)[C@@H](N)CC([O-])=O OPSXJNAGCGVGOG-DKWTVANSSA-L 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000402754 Erythranthe moschata Species 0.000 description 1
- 244000004281 Eucalyptus maculata Species 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- CITFYDYEWQIEPX-UHFFFAOYSA-N Flavanol Natural products O1C2=CC(OCC=C(C)C)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C=C1 CITFYDYEWQIEPX-UHFFFAOYSA-N 0.000 description 1
- 206010072132 Fracture pain Diseases 0.000 description 1
- XYZZKVRWGOWVGO-UHFFFAOYSA-N Glycerol-phosphate Chemical compound OP(O)(O)=O.OCC(O)CO XYZZKVRWGOWVGO-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 239000004158 L-cystine Substances 0.000 description 1
- 235000019393 L-cystine Nutrition 0.000 description 1
- 229930195714 L-glutamate Natural products 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 229930182844 L-isoleucine Natural products 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 241000995070 Nirvana Species 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 108010001441 Phosphopeptides Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 238000003723 Smelting Methods 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 208000014151 Stomatognathic disease Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 208000010641 Tooth disease Diseases 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N Xylose Natural products O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000003732 agents acting on the eye Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 229960004543 anhydrous citric acid Drugs 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000003262 anti-osteoporosis Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000003208 anti-thyroid effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 229940125714 antidiarrheal agent Drugs 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 230000009876 antimalignant effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940125688 antiparkinson agent Drugs 0.000 description 1
- 239000003904 antiprotozoal agent Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 229940043671 antithyroid preparations Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 235000015197 apple juice Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000004380 ashing Methods 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 description 1
- 229960001671 azapropazone Drugs 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000003130 blood coagulation factor inhibitor Substances 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- WUKWITHWXAAZEY-UHFFFAOYSA-L calcium difluoride Chemical compound [F-].[F-].[Ca+2] WUKWITHWXAAZEY-UHFFFAOYSA-L 0.000 description 1
- 229910001634 calcium fluoride Inorganic materials 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- 239000001362 calcium malate Substances 0.000 description 1
- OLOZVPHKXALCRI-UHFFFAOYSA-L calcium malate Chemical compound [Ca+2].[O-]C(=O)C(O)CC([O-])=O OLOZVPHKXALCRI-UHFFFAOYSA-L 0.000 description 1
- 229940016114 calcium malate Drugs 0.000 description 1
- 235000011038 calcium malates Nutrition 0.000 description 1
- 229940095672 calcium sulfate Drugs 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- CNYFJCCVJNARLE-UHFFFAOYSA-L calcium;2-sulfanylacetic acid;2-sulfidoacetate Chemical compound [Ca+2].[O-]C(=O)CS.[O-]C(=O)CS CNYFJCCVJNARLE-UHFFFAOYSA-L 0.000 description 1
- PBUBJNYXWIDFMU-UHFFFAOYSA-L calcium;butanedioate Chemical compound [Ca+2].[O-]C(=O)CCC([O-])=O PBUBJNYXWIDFMU-UHFFFAOYSA-L 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013522 chelant Chemical class 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940124568 digestive agent Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- VIYFPAMJCJLZKD-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate Chemical compound [Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 VIYFPAMJCJLZKD-UHFFFAOYSA-L 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 150000002206 flavan-3-ols Chemical class 0.000 description 1
- 235000011987 flavanols Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 235000015201 grapefruit juice Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 description 1
- AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 description 1
- 235000010209 hesperetin Nutrition 0.000 description 1
- 229960001587 hesperetin Drugs 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 239000000077 insect repellent Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000015122 lemonade Nutrition 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940023490 ophthalmic product Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229960003540 oxyquinoline Drugs 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 229940044652 phenolsulfonate Drugs 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 239000011814 protection agent Substances 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 229960003581 pyridoxal Drugs 0.000 description 1
- 235000008164 pyridoxal Nutrition 0.000 description 1
- 239000011674 pyridoxal Substances 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 150000008264 rhamnoses Chemical class 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- YFNCATAIYKQPOO-UHFFFAOYSA-N thiophanate Chemical compound CCOC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OCC YFNCATAIYKQPOO-UHFFFAOYSA-N 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 150000008135 α-glycosides Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
- A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/794—Ketones containing a keto group bound to a six-membered aromatic ring having unsaturation outside an aromatic ring
- C07C49/796—Ketones containing a keto group bound to a six-membered aromatic ring having unsaturation outside an aromatic ring polycyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/82—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
- C07C49/83—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups polycyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/82—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
- C07C49/835—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups having unsaturation outside an aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/83—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/32—2,3-Dihydro derivatives, e.g. flavanones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
- C07D311/62—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2 with oxygen atoms directly attached in position 3, e.g. anthocyanidins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Physical Education & Sports Medicine (AREA)
- Mycology (AREA)
- Botany (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Birds (AREA)
- Inorganic Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Description
1331032 A7 _____B7_ 五、發明説明(1 ) 本發明係有關骨質或牙齒組織等含鈣組織中可增加鈣 量所使用之增強含鈣組織用劑及其用途者◊ (請先閲讀背面之注意事項再填寫本頁) 先行技術中,通常伴隨年齡增長、骨質、牙齒等含鈣 組織引起脆化。骨質組織中,不斷的骨形成與骨吸收被生 成之,通常年輕時,可平衡骨形成與骨吸收者》惟,過於 絕食,伴隨加齡導致荷爾蒙失衡等各種因素使得骨形成與 骨吸收失調,傾向骨吸收。此時,長期持續後,由骨質、 牙齒等含鈣組織減少重要組成成份之鈣,易產生骨質疏鬆 、骨折、腰痛等骨疾病、或蛀牙、牙周病等牙齒疾病。 經濟部智慧財產局員工消費合作社印製 生體內的鈣係於含鈣組織中以羥基磷灰石等磷酸鈣鹽 之形態做成固體狀態存在後,形成骨質及牙齒,不僅擔任 增強其組織之要角,亦做爲身體必要鈣離子之供給源。本 國有鈣攝取量不足之虞、市販上有各種增強鈣質之各種健 康食品販售之。惟,僅攝取鈣質,並未出現理想吸收效率 者’且’攝取過量時將陷入局耗血绩之危險域中,因此, 鈣之攝取方法非慎重不可。骨質、牙齒等含鈣組織中,使 鈣沈著,以適當鈣做爲營養素攝取後,爲更加吸數,代謝 而攝取鎂等其他鑛物質者被推崇者。惟,其效果並不明顯 。又,除該鐮物質之外,亦進行投用維他命D、降鈣素製 劑 '雌激素製劑、蛋白質同化激素製劑,雙磷酸鹽等油性 維他命、激劑者。此方法比僅攝取鑛物質之效果較爲理想 ,惟,使用油溶性維他命劑、激劑時,其投用程序較爲煩 雜,過剩投用後恐產生副作用,並未能完全令人滿意。 本發明以提供一種無毒、安全,且作用效果高之增強 本紙張尺度適用中.國國家標準(CNS ) A4規格(210X297公釐) -4 - 1331032 A7 ________B7___ 五、發明説明(2 ) 含耗組織用劑及摻合此所製成之飲食品 '化粧品、及醫藥 品等用途爲課題者。 (請先聞讀背面之注意事項再填寫本頁) 〔發明開示〕 本發明者針對植物成份,進行精密硏討後,意外發現 ’後述具有一般式1至5任一所示基本結構之物質或其前 驅物(以下,亦記成本明細書中一般式1至5之物質)使 動物鈣代謝往鈣沈著方向誘導後,於含鈣組織增強使鈣沈 著之組織後,其結果增加骨重量者。更使異黃酮類與一般 式1至5之物質共同使用後,則使動物之鈣代謝往鈣沈著 方向進行誘導,含鈣組織中增強鈣沈著組織,其結果增加 骨重量,進而完成本發明。 亦即,本發明係提供一種含一般式1至5之物質,如 :含有1種或2種以上之黃酮類、黃酮醇類、黃烷酮類、 二氫黃酮醇類、花色素類、黃烷醇類、芳基丙烯醯芳烴類 ’或噢嗫類、或其前驅物之增強含鈣組織用劑做爲有效成 份者。 經濟部智慧財產局員工消費合作社印製 本發明更提供一種該物質同時含有異黃酮類之增強含 鈣組織用劑者。 本發明又提供一種摻合該增強含鈣組織用劑所成之飮 食品' 化粧品、醫藥品等用途者。 〔圖面之簡單說明〕 圖1係代表鹼磷酸酶活性增強作用中山萘黃素、桔皮 本紙張尺度適用中.国國家標準(CNS ) A4規格(210X297公釐) -5- 1331032 A7 B7 五、發明説明(3 ) 素或ipriflavone各濃度之經日變化圖。 (請先W讀背面之注意事項再填寫本頁) 圖2係代表鈣沈著增強作用中山萘黃素、ipriflavone各 濃度之經日變化圖。 圖3係代表鈣沈著增強作用中山萘黃素與ipriflavone 各濃度之倂用效果圖者。 圖4係代表鈣沈著增強作用中桂皮素與ipriflavone各 濃度之倂用效果圖。 〔發明實施之最佳形態〕 經濟部智慧財產局員工消費合作社印製 針對此發明之實施形態進行說明後,本發明所使用之 一般式1至5物質係屬原本做爲植物成份廣範分布之類黃 酮所屬物質者。具有一般式1之基本結構物質稱爲黃酮類 、黃酮醇類、黃烷酮類、二氫黃酮醇類者,如:R i爲氫原 子者,且,X爲雙鍵爲其特徵之黃酮類,Ri爲羥基(或藉 由某糖類被配糖化者),且,X爲雙鍵者爲特徵之黃酮醇 類,尺:爲氫原子’ X爲單鍵者爲其特徵之黃烷酮類,Rl 爲羥基(或藉由某糖類被配糖化者),且,X爲單鍵者爲 其特徵之二氫黃酮醇類者。本發明中,可使用做爲具有一 般式1之基本結構物質之表1所示物質者。又,表1中, Η代表氫原子,0H代表羥基、〇 CH3代表甲氧基、 〇G 1 u爲被配糖化之葡萄糖、〇Rh a爲被配糖化之鼠 李糖'ORut爲被配糖化之芸香糖。 < —般式1 : 本紙張尺度適用中.國國家標準(CNS ) A4規格(2丨0X297公釐) -6- 1331032
A7 B7 五、發明説明(4 ) R6 R7 式中,X代表單鍵或雙鍵,只1至111〇代表任意取代 基者。) (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 本紙張尺度適用中.國國家標準(CNS ) A4規格(210X297公釐) 1331032 A7 B7 五、發明説明(5 ) 經濟部智慧財產局員工消費合作社印製 X 驟 盤 ttwl 1 m 盤 加11 驟 缴 t*w1 1 m |*W11 m 盤 <*w,l 職 驟 驄 »*·»" m 癱 加1 1 m t*w1l 職 懲 »*w1 1 m 驄 盤 ι*τ«,Ι m 態 »*»t1 1 m <*w1l m 鳙 «♦mi m 鳙 IK IK SK ti 飘 m a SK a 默 m SK SK Sfflf Λ 酹 Dml nfflf 酹 酹 酙 酹 Λ 輒 〇 Ρί X X X X re X X X X X X X X X X X X X X pci X X X X X X X! 'X 〇 X X, X X 〇 X X X X X X X X X Pi X K OH OH OCHb 0CH3 K OH X 〇 OH i OH_I PC: 〇 1 OH_I 1 OH__I OH 1 OHI OH ί X X 〇 〇 OCH3 X 〇 \ OH 1 OH OCH3 〇 DC 〇 ¢5 s rr: 〇 X X K OH OH Ί OH 「och3] X 1 OH | OH 1 OH X X αΰ X 〇 OH OH X 〇 o Ό X tc 丈 X X X X X 〇 X X X X: X X X X X X: X ού X X X X X 工: X tc X X K 工 x XI 工: P:: P:: :c Ρύ κ Pi 〇 OH X 〇 〇 ORut 〇 〇 OH OH o 1 _ OH_! 1 OH_I OH 1 OH_I K 〇 X X o OCH3 OH X 〇 | OCH3 1 ORha ORut OH OH 0^ X tr: Dd X K X X X OH 'X X X X X x: X X OH OH 〇 sc ο OH X X 〇 | OH X 〇 1 OH 1 o 1 OH I o 1 OH 1 〇 1 〇 HJ Π: 〇 工: ο OH OH | OGlu 1 OH X 〇 X 〇 οά X DC PC X X 〇 ο X 〇 OH rr: 〇 1 OH I 丨OH—_—」 I OGlu 丨 ORha | ORut ! ORha :c χ: o 〇 m m m 枨 m m 赋 m 氍 账 瓶 诽 IK 賦 m m 9n m m 昏 m 窓 m m m Μ m 涅 匾 m w 遒 m 蜘 辑 ss tin 掛 m 货 扭 it 展 mil ΙΠη m a 蜜 戗 摊 輒 蜜 m M 塾 剮 m s m (請先閲讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準(CNS ) Α4規格(210Χ297公釐) -8- 1331032 A7 ___B7_ 五、發明説明(6 ) 具有一般式2之基本結構物質稱爲花色素物質者,本 發明中,如表2所示化合物被使用之。又,表2中,Η代 表氫原子、ΟΗ代表羥基' 〇ch3代表甲氧基、〇G 1 u 爲被配糖化之葡萄糖者。 一般式2 : ----------- (請先閲讀背面之注意事項再填寫本頁) 訂
1331032
7 7 A B 經濟部智慧財產局員工消費合作社印製 五、發明説明(7 ) 工 工 I 工 工 工 工 CO CO ΓΟ 工 工 〇 〇 〇 〇 〇 〇 〇 Μ PC 工 工 工 X X X 〇 〇 〇 〇 〇 〇 τ 工 工 JO CO 〇 工 〇 〇 〇 〇 〇 工 工 工 工 工 X 工 工 工 工 X 工 工 工 工 工 工 工 〇 〇 〇 〇 〇 〇 工 工 工 工 工 工 工 工 工 X I X 〇 〇 〇 〇 〇 〇 工 工 工 工 X 7n 〇 〇 〇 〇 〇 〇 绅I m CO 账 驸 駙 滌 账 撕 酿 Φ & 去1 11 1 1 (請先閱讀背面之注意事項再填寫本頁) 本紙張尺度適用中.國國家標準(CNS ) A4規格(210X297公釐) -10- 1331032 A7 B7 五、發明説明(8 ) 具有一般式3基本結構之物質稱黃酮醇類之物質者, 本發明中如表3所示之化合物被使用之。又,表3中,Η 代表氫原子、Ο Η代表羥基。 一般式3 :
Re R7
R2 (式中,尺:至只!。代表任意取代基者。) (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 本紙張尺度適用中.國國家標準(CNS ) A4規格(210X297公釐) -11 - 1331032 A7 B7 五、發明説明(9 ) 經濟部智慧財產局員工消費合作社印製 〇 oi 工 工 X 工 Ο 工 工 〇 I X 工 〇 〇 〇 工 工 〇 工 〇 工 工 工 X 工 工 工 工 工 〇 〇 〇 工 工 工 工 工 工 〇 〇 〇 工 工 工 〇 〇 〇 掩 氍 塑 m 撇 ---------衣—^ (請先閲讀背面之注意事項再填寫本頁) IP-· 本纸張尺度適用中.國國家標準(CNS ) A4規格(2!OX:297公釐) -12- 1331032 A7 B7 五、發明説明(10 ) 具有一般式4基本結構之物質被稱爲芳基丙烯醯芳烴 類物質者,本發明中如:表4所示化合物被使用之。又, 表4中,Η代表氫原子、〇Η代表羥基。 一般式4 :
(式中,Ri至Rii代表任意取代基。) (請先閲讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 本紙張尺度適用中.國國家標準(CNS ) A4規格(210X297公釐) -13- 1331032 A7 B7 五、發明説明(11 ) 經濟部智慧財產局員工消費合作社印製 X 工 〇 〇 工 工 工 工 工 工 〇 工 工 X 工 工 工 工 I 〇 工 工 X I 〇 X 工 名稱 芳基丙烯 醯芳烴 根皮素 I--------衣-- (請先閲讀背面之注意事項再填寫本頁)
、1T 本紙張尺度適用中.國國家標準(CNS ) Α4規格(210Χ297公釐) -14- 1331032 A7 B7 五、發明説明(12 ) 具有一般式5基本結構之物質被稱爲噢嗦類之物質者 ,本發明中,如:表5所示化合物被使用之。又,表5中 者 基 氧 甲 表 代 3 Η C ο 、 基 羥 表 代 Η ο 子 原 氫 表 代 Η 式 般
8 R 者 基 代 取 意 任 表 代 ο IX R 至 2 R 中 式 (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 本紙張尺度適用中.國國家標準(CNS ) Α4規格(210Χ297公釐) -15- 1331032 A7 B7 經濟部智慧財產局員工消費合作社印製 五、發明説明(13 ) 〇 οά X X 工 工 ce 工 工 〇 〇 工 工 〇 〇 工 工 η 工 〇 〇 工 工 〇 〇 工 工 工 X 睬 {Η m m m 粜 ---------11^衣— (請先閲讀背面之注意事項再填寫本頁) 本纸張尺度適用中.國國家標準(CNS ) A4規格(210 X 297公釐)
*1T 1331032 A7
五、發明説明(14 ) (請先聞讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 本發明所使用之一般式1至5物質,亦即,黃酮類' 黃酮醇類、黃烷酮類、二氫黃酮醇類、花色素類、黃院醇 類' 芳基丙烯醯芳烴類及噢嘮類,或其前驅物通常使用之 配基、或配糖體形態者。又,存在於其聚合物等天然之衍 生物’或不具一般式1至5之基本結構 '攝取後,藉由體 內代謝後,結構變化後,於具有一般式1至5所示基本結 構之物質上進行變化之物質,所有衍生物均可增強含鈣組 織之鈣者即可。此者有花色素類之一種花青素前驅物之原 花色素 '原花色素聚合物之原花色素聚合物(柿子單寧) 等者。一般式1至5之物質或其衍生物不管其來源、純度 、必要時,以適當溶媒萃取含較多量之植物材料後,直接 利用取得之萃取液,更可精製後,提高純度使用之。另外 ’亦可使用人工合成取得者,或市販品均可適用之。又, 必要時,藉由適當化學性,或生化學之方法使甲基化、乙 基化、甲氧基化 '乙氧基化、硫酸化、配糖化等衍生物化 '聚乙二醇等水溶性高分子進行結合之,做爲提昇水溶性 及/或安定性之衍生物之利用亦有利其進行者。做爲此例 者如:α -糖基芸香苷(商品名PaG芸香苷P』股份公 司林原商事販賣)、〇: -糖基桔皮苷(商品名『aG桔皮 苷』股份公司林原商事販賣)、甲基化桔皮苷(AIPS藥品 工業販賣)、α-糖基槲皮黃素、α -糖基柚苷等。使用 不易溶於水中之物質時,在不損及本發明效果範圍下,必 要時可藉由二甲亞硕、乙醇等溶媒進行溶解之,或利用海 藻糖等糖質溶解,或以懸浮狀態亦可有利進行之。 本紙張尺度適用中國國家標準(CNS ) Α4規格(210X297公釐) -17- 1331032 A7 _____B7________ 五、發明説明(15 ) (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 又,本發明所使用一般式1至5之物質倂用公知之骨 質疏鬆治療或預防作用之異黃酮類時,具有明顯相乘增強 強化含鈣組織之作用特徵者。異黃酮類係具有一般式6所 示結構物質之總稱者,做爲本發明增強含鈣組織用劑所摻 合之物質者可使用該配基以及/或該配糖體者。如··本發 明中表6所示物質例者,適於摻合於本發明增強含鈣組織 用劑。異黃酮類只要可對於發揮本發明所使用之一般式1 至5物質之含鈣組織的鈣沈著作用可更爲增強者即可,不 管其來源,純度,必要時以適當溶媒萃取含較多量植物材 料後,直接使用該取得萃取液,更可進行精製後,提高純 度後使用之。做爲此例者有大豆異黃酮者。又,亦可適當 使用人工合成者,或市販品均可,使用不易溶於水之物質 時’在不損及本發明效果範圍下,必要時亦可使用二甲亞 硕、乙醇等之溶媒、溶解後利用之。與α,α—海藻糖等 糖質用時溶解,或,於懸浮狀態下亦可有利進行之。另外 ’必要時’更藉由適當化學’或生化學方法進行修飾後, 進行甲基化、乙基化、甲氧基化、乙氧基化、硫酸化、配 糖化等之處理,做成提昇水溶性及/或安定性之衍生物使 用後亦有利於實施者。做爲比例者如:Ω Μ宜坦基麵去 —般式6 : 本纸張又度適用中.國國家標準(CNS ) Α4規格(210Χ297公釐) -18- 1331032 A7 B7 五、發明説明(16
8 R 者 基 代 取 意 任 表 代 ο 1R 至R 中 式 ---------衣— (請先閲讀背面之注意事項再填寫本頁)
,1T f 經濟部智慧財產局員工消費合作社印製 本纸張尺度適用中.國國家標準(CNS ) A4規格(21〇Χ:297公釐) -19- 1331032 7 Β 五、發明説明(17 ) 經濟部智慧財產局員工消費合作社印製
〇 I 工 I 工 工 工 工 工 X 工 工 工 I 工 工 〇 〇 〇 〇 I X 工 工 X X 工 工 工 工 X 工 工 工 工 卜 ¢0 工 a 工 1 1 1 < Ο 〇 〇 〇 〇 〇 〇 〇 ¢5 X 工 X 工 工 工 工 〇 工 工 〇 工 工 X I 工 工 <〇 c 〇 FTn7 > cd W 长 长 • V-4 $ W 〇, 赋 涨 U (請先閲讀背面之注意事項再填寫本頁) 衣
、1T 本紙張尺度適用中.國國家標準(CNS ) Α4規格(210Χ297公釐) -20- 1331032 Α7 Β7 五、發明説明(18 ) (請先閲讀背面之注意事項再填寫本頁) 本發明之含鈣組織係指如:羥基磷灰石等之磷酸鈣鹽 較多量存在之組織者,此組織例如:骨組織,特別是硬骨 組織,及牙齒組織之例,此組織中具有發揮本發明增強含 鈣組織用劑之效果者。 本發明增強含鈣組織用劑除有效成份之一般式1至5 物質,或一般式1或5物質及異黃酮類之外,必要時可含 有如:無水矽酸,合成矽酸鋁、乳糖、α,α -海藻糖、 α,々-海藻糖、阿拉伯膠、玉米澱粉、結晶纖維素等賦 形劑、羧甲基纖維素、聚乙烯吡咯烷酮等結合劑、硬脂酸 鎂、滑石等潤滑劑、澱粉、羧甲基纖維素鈣等崩散劑、水 、乙醇等溶媒等者。又,藉由此等可做成粉末、顆粒、錠 劑、液狀、糊狀、懸浮狀等適當形態者。特別針對αα —海藻糖被揭示於特開2 0 0 0_3 8 3 4 3號公報及特 開2000—198736號公報爲具有利於骨質疏鬆症 之預防,治療之用者。 經濟部智慧財產局員工消費合作社印製 做爲本發明增強含鈣組織用劑之有效成份含一般式1 至5物質,或一般式1至5物質及異黃酮類可做爲有效成 份之摻合’或有效成份與製劑上可容許載體或稀釋劑相互 混合物任意製劑使用之。製劑中有效成份量以無水物換算 下以0 · 000 1重量%以上者宜,較佳者爲〇 . 〇〇1 重量%以上者。本發明增強含鈣組織用劑可以口服、非經 口投用任意投用法。本發明增強含鈣組織用劑之投用量依 其投用形態、投服對象不同,投與足夠量可發揮本發明效 果,因此,無限制投用量之必要,惟,一般如表記爲準, 本紙張尺度適用中.國國家標準(CNS ) Α4規格(210X297公釐) -21 - 1331032 A7 _____B7_ 五、發明説明(19 ) (請先聞讀背面之注意事項再填寫本頁) 以人體爲對象時,一般分一次或數次投用後,1日有效成 份量爲0·1〜500mg/kg體重,較佳者爲0.5 〜200mg/kg體重者。 做爲本發明增強含鈣組織用劑之有效成份所使用之一 般式1至5物質,或一般式1至5物質及異黃酮做爲食品 添加物、化粧品原料、醫藥品原料等被確定多半具安全性 者’做爲增強含鈣組織用劑者更摻合此所成之飲食品、化 粧品、或醫藥品亦極具安全性,可進行投用、攝取或使用 之。 做爲本發明增強含鈣組織用劑之適用對象者以具有以 固體狀鈣做爲主成份之骨組織、齒組織之動物,亦即,人 或人以外之哺乳類所含有之脊椎動物總體爲可適用對象者 c 經濟部智慧財產局員工消費合作社印製 本發明增強含鈣組織用劑係可有效發揮伴隨骨質疏鬆 症、骨折等骨相關疾病、蛀牙及牙周病之齒槽骨的化等牙 齒相關疾病之治療、促進恢復、或其預防者。更可用於其 他疾病之治療等所投用之激素、細胞分裂劑等藥劑之副作 用之骨吸收,脫灰之骨量降低之防止,天然骨或人工骨利 植時定著促進之使用。另外,可用於防止正常人各種骨量 下降,如使閉經後或產前產後女性激素分泌異常造成骨量 下降,過度絕食,營養失調所造成激素分泌異常後骨量之 下降,高齡者長期臥床、上下肢麻痺、長期入院等長期臥 床後,運動不足造成骨量下降、宇宙、水中生活之無重力 或低重力造成骨量下降,過度運動訓練等造成骨量降低之 本紙張尺度適用中.國國家標準(CNS ) A4規格(2丨OX297公釐) -22- 1331032 A7 B7 五、發明説明(20) (請先閲讀背面之注_項再填寫本頁) 恢復,發揮預防骨量下降之效果。另外亦可有效促進幼兒 成長時骨形成,維持高齡者之骨量。更使血漿中之鈣沈著 於含鈣組織中,因此,依其使用方法後,亦可期待有效改 善高鈣血漿者。以上效果,不限於人類,亦有利適用於犬 、貓、牛、豬、馬、鹿'犀牛、象、山藉等脊椎動物者。 經濟部智慧財產局員工消費合作社印製 摻合醫藥品之本發明增強含鈣組織用劑必要時與本發 明增強含鈣組織用劑之有效量同時倂用先行公知之骨質疏 鬆治療藥後可期待更高度之效果。做爲骨質疏鬆治療劑者 如:降鈣素製劑、雌激素製劑、雙磷酸鹽製劑、維他命D 製劑、維他命K製劑等例。又,一般其他常用藥品如:麻 醉劑、催眠鎭痛劑、抗不安劑、抗癲癎劑、解熱鎭痛消炎 劑,興奮劑、覺醒劑、抗帕金森氏劑、精神神經用藥、中 樞神經劑、骨格肌弛緩劑 '自律神經用劑、鎭痙劑、眼科 用藥、耳鼻科用藥 '鎭暈劑、強心劑、不整脈用藥、利尿 劑、降血壓劑、血管收縮劑、冠狀血管抗張劑、末梢血管 擴張劑 '高脂血症劑、呼吸促進劑 '鎭咳袪痰劑 '支氣管 擴張劑 '過敏症用劑、止瀉劑、整腸劑、消化性潰瘍治療 劑 '健胃消化劑、制酸劑、利膽劑、腦下垂體激素劑、唾 液腺激素劑、甲狀腺激素劑、抗甲狀腺激素劑、蛋白同化 類固醇劑、副腎皮質激素劑、男性激素劑、卵胞激素劑、 黃體激素劑、混合激素劑、泌尿生殖器劑、肛門劑、外科 用殺菌消毒劑·、創傷保護劑、化膿性疾病用外用劑、鎭痛 劑、止癢劑、收歛劑、消炎劑、寄生蟲皮膚疾病外用劑、 皮膚軟化劑、腐蝕刻、齒科、口腔用劑、維他命劑、無機 本纸張尺度適用中.國國家標準(CNS ) A4規格(210X297公釐) -23- 1331032 A7 _____B7___ 五、發明説明(21 ) (請先閱讀背面之注意事項再填寫本頁) 質製劑、補液劑、止血劑、血液凝固阻止劑、肝臟疾病用 劑' 解毒劑、習慣性中毒用劑、痛風治療劑、酵素製劑、 糖尿病用劑、抗惡性腫瘤劑、抗組織胺劑、刺激療法劑、 抗生物質、化學療法劑 '生物學製劑、驅蟲劑、抗原蟲劑 '調製用劑、X線造影劑及診斷用藥等藥劑,更易於取得 本發明增強含鈣組織用劑者,如:可適當摻合1種或複數 之補助劑、增量劑、稀釋劑、賦形劑、安定劑、防腐劑、 著色劑、著香劑等,依其使用形態可調製如:萃提劑、酏 劑、膠囊劑、顆粒劑、九劑、眼軟膏劑、懸浮劑、乳劑、 硬膏劑、栓劑、散劑、酒精劑、錠劑、糖漿劑、浸劑、煎 劑、注射劑、酊劑 '點眼劑、含錠劑、軟膏劑、糊劑、芳 香水劑、塗抹劑、檸檬水劑、流萃提劑、水劑、飮料劑、 更於必要時,可調製成點鼻劑、噴鼻劑、下呼吸道用吸入 劑、眼科用緩釋劑、口腔粘膜貼附劑、灌腸劑等。 本發明增強含鈣組織用劑完成該調製步驟中只要藉由 混合、捏混、溶解、浸漬、散佈、塗佈、噴霧、注入等方 法後含所定量之有效成份者即可》 經濟部智慧財產局員工消費合作社印" 又,本發明所使用一般式1至5之物質及異黃酮爲充 份發揮其作用效果’亦即於含鈣組織中使鈣沈著作用,最 好攝取礦物質,特別是與鈣化合物相同者,含於本發明之 增強含鈣組織用製者爲宜。又,摻合此增強含鈣組織用劑 之飮食品、化粧品或醫藥品更摻合後可更有利進行之。做 爲鈣化合物者如··氯化鈣、甘油磷酸耗、葡糖酸鈣、乳酸 釣、碳酸銘、磷酸氫釣 '磷酸二氫耗、何泮酸錦、沉酸耗 本紙張尺度適用中國國家標準(CNS〉A4規格(210X297公釐)—"~ ---- -24- 1331032 A7 _______B7__ 五、發明説明(22) (請先閲讀背面之注意事項再填寫本頁) 、氟化鈣、硫代二醇酸鈣、硫酸鈣、矽酸鈣、醋酸鈣、L -天冬胺酸鈣、檸檬酸鈣、蘋果酸鈣、琥珀酸鈣等例,此 等可以1種或組合2種以上使用之。 更爲發揮本發明增強含鈣組織用劑之作用效果,與該 鈣化合物之同時除鈣以外之礦物質,如:鉀、鈉、鎂、錳 '磷、鐵、鋅等均衡良好之摻合者宜。特別是鎂化合物可 防止高鈣血漿等之外同時亦攝取鈣爲宜者,鎂化合物對於 本發明增強含鈣組織用劑之摻合量爲鈣化合物之等莫耳以 下者宜,較佳者當1莫耳鈣化合物時爲0 . 5莫耳至0.05 莫耳之範圍下被摻合之。做爲鎂化合物者如:氧化鎂、氯 化鎂、碳酸鎂、硫酸鎂等例,此等可以1種或組合2種以 上者使用之。 經濟,部智慧財產局員工消費合作社印製 另外,礦物質於腸內易呈不溶化,因此,吸收效率容 易下降,因此將有利腸管吸數,具有對於生體之利用性提 高之礦物質吸收促進作用之物質含於本發明增強含鈣組織 用劑者亦可利於實施。例如:酪蛋白磷肽等蛋白質或低聚 肽、異麥芽低聚糖、左旋糖低聚糖、木糖低聚糖、左旋蔗 糖、大豆低聚糖、α,海藻糖、α,海藻糖、乳 糖等低聚糖、乳糖、醋酸、檸檬酸、葡糖酸、琥珀酸等有 機酸例,可有效利用之。 又,爲更發揮本發明增強含鈣組織用劑之作用效果, 使維他命類含於本發明增強含鈣組織用劑者爲佳。做爲維 他命類之例者如:活性型維他命D、維他命Κ、L -抗壞 血酸,或其衍生物等例者。 本紙浪尺度適用中周國家標$ ( CNS ) Α4規格(2丨0X297公— -25 - 1331032 A7 __ _B7_____ 五、發明説明(23 ) 以下,藉由實驗進行本發明說明。 (請先閲讀背面之注意事項再填寫本頁) 〔實驗1〕以鹼磷酸酶活性做爲指標之各種有機化合物的 檢索 使具有鈣沈著作用之骨芽細胞數量增加後可增加骨量 者爲其重點者,因此,使老鼠前骨芽細胞株MC 3 T 3 -E1細胞(RCB1126,理硏genbank)對骨芽細胞分 化之物質針對做爲植物成份之公知有機化合物進行檢索。 採用測定前骨芽細胞中活性低,前骨芽細胞所分化之骨芽 細胞中活性高者爲公知之鹼磷酸酶活性後,做成其指標。 〔老鼠前骨芽細胞之培養〕 藉由示於表7中含1 0 mMHEPES、10 ( v / v ) %牛 胎兒血淸(gibco BRL公司販賣)之組成冷一 MEM培養基 p Η 6 _ 8後,調製成細胞濃度5 X 1 0 4個/m 1之老鼠 前骨芽細胞株河03丁3-£1後,2 4孔感光板([&1让〇11 經濟,部智慧財產局員工消費合作社印製 becton dikinson公司販賣)中1孔播種1ml之5x 1 04 個細胞,使細胞附著於感光板底面爲止,於5 %碳酸氣體 氣氛下進行培養之。去除培養基後,使溶於乙醇之有機化 合物,亦即,消炎痛(funacoshi股份公司販賣)(陽性對照 )、山萘黃素(funacoshi股份公司販賣)' 沒食子酸( nacalaitesk股份公司販賣)、咖啡酸(和光純藥工業股份公司 販賣)、4 -甲基傘形酮(和光純藥公司販賣)、咖啡因(和光 純藥工業股份公司販賣)、万一葉紅素(sigma公司販賣) 本纸張尺度適用中國國家標準(CNS > A4規格(210X297公楚j '-- -26- 1331032 A7 _ _B7__ 五、發明説明(24) 、甘草酸(片山化學工業股份公司販賣)、薄荷醇(和光純藥 工業股份公司販賣)、茶鹼(和光純藥工業股份公司販賣)' 生育酚(sigma公司販賣)、香草醛(和光純藥工業股份公 司販賣)各以lm 1添加分別含有2 〇#M濃度之 MEM培養基(含1 〇% (v/v)牛胎與血淸、1 〇 m Μ β -甘油磷酸醋)者。又,由於培養基中含有最終 濃度0 . 2 % ( ν / ν )乙醇,因此’做爲陰性對照者’ 爲含有0 . 2% (ν/ν)乙醇之α — MEM培養基者。 連續使放置3天含新鮮之各試料培養基’或未含其之培養 基相互交替培養8天。 (請先閲讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 -27- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 1331032 A7 B7 五、發明説明(25 ) 經濟部智慧財產局員工消費合作社印製 表7 成分 mg/1 成分 mg/1 L-丙胺酸 25 L-抗壞血酸 50 L-精胺酸 105 生物素 0.1 L-天冬醯胺 25 膽驗 1 L-天冬胺酸 30 氰鈷胺素 1.36 L-半胱胺酸 100 葉酸 1 L-胱胺酸 24 肌醇 2 L-谷胺酸 75 煙醯胺 1 L -谷醯胺 292 汎酸 1 甘胺酸 50 吡哆醛 1 L-組胺酸 31 核黃素 0.1 L-異白胺酸 52 硫胺素 1 L-白胺酸 52 氯化鈣 200 L-賴胺酸 58 氯化鉀 400 L-蛋胺酸 15 氯化鎂 200 L-苯基丙胺酸 32 氯化鈉 6,800 L-脯胺酸 40 碳酸氫鈉 2,000 L-絲胺酸 25 磷酸二氫鈉 150 L-蘇胺酸 47.6 葡萄糖 1,000 L-色胺酸 10 硫辛酸 0.2 L-酪胺酸 36 酚磺酞 10 L-纈胺酸 46 丙酮酸鈉 110 (請先閲讀背面之注意事項再填寫本頁) 本紙張尺度適用中.國國家標準(CNS ) A4規格(210 X 297公釐) -28- 1331032 A7 B7 五、發明説明(26) 〔鹼磷酸酶活性之測定〕 鹼磷酸酶活性之測定係利用鹼磷/3 - T e s t和光(和光,純 藥工業股份公司販賣),依kasi等方法爲基準進行(
Archives of Oral Biology) ’ 第 44 卷、2 3 3 〜2 4 1 頁(1 9 9 9 ))。亦即,由上記老鼠前骨芽細胞去除培 養基後,以lml之0 · 2 5M蔗糖溶液進行洗淨3次, 依序添加0 . 4 5ml之含有ImM氯化鎂,含50mM 蔗糖之50mM碳酸鹽緩衝液pH9 . 8者,0 . 05 ml之3 . 4mM對-硝苯磷酸二鈉,於2 5°C下放置5 分鐘後,添加1 . 5ml之0 . 6N氫氧化鈉後使反應停 止之。該反應液中藉由鹼磷酸酶作用所生成之對-硝基苯 酚之量測其波長4 0 5 n m之吸光度後,以該値做爲鹼磷 酸酶活性者。表8顯示各試料中添加含鹼磷酸酶活性與 0 . 2 % ( v / v )乙醇之培養基之陰性對照活性比的相 對活性整理表。 (請先聞讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 本纸張尺度適用中.國國家標準(CNS ) A4規格(210X297公釐) -29- 1331032 A7 B7 五、發明説明(27 ) 有機化合物 相對鹼磷酸酶活性(%). 0.2% (ν/ν)乙醇 100 消炎痛 142 山萘黃素 1 62 .... 沒食子酸 79 -.- 咖啡酸 97 4 一甲基傘形酮 96 ... 咖啡因 100 /3 —葉紅素 8 1 甘草酸 97 薄荷醇 95____ 茶鹼 92 生育酚 100 香草醛 89 (請先閲讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 -準 一 I 國 國. 中 用 適 度 幻 I張 纸 I本 由表8結果證明山萘黃素比陽性對象之消炎痛其老鼠 前骨芽細胞株(M C 3 T 3 - E 1 )之鹼磷酸酶活性較爲 增加。此結果顯示山萘黃素使老鼠前骨芽細胞之鹼磷酸酶 活性增強,因此,前骨芽細胞於骨芽細胞具有分化作用者 〔實驗2〕以鈣沈著作用做爲指標之各種有機化合物的檢 索 (CNS > A4^tM 210 X297公釐) -30 1331032 A7 B7 五、發明説明(28) (請先閲讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 實驗1中進行檢測由含有各種有機化合物被驗試料所 具前骨芽細胞對骨芽細胞之分化衍生促進作用。再進行檢 測實際上所增強之鈣沈著作用。做爲有機化合物例者使用 如:消炎痛(funacoshi股份公司販賣)(陽性對照),山萘 黃素(funacoshi股份公司販賣),梧皮素(funacoshi股份公 司販賣),没食子酸(nakalaitesk股份公司販賣),咖啡酸( 和光純藥工業股份公司販賣)者。此等分別以2 0 V m濃度 含有之α— MEM培養基(含1 〇% (v/v )牛胎兒血 淸,lOmMyS -甘油磷酸酯)添加於每lml老鼠 MC3T3-E1細胞株中。又,培養基中含最終濃度〇 . 2 % ( v / v )乙醇,因此,做爲陰性對照者爲含有〇 . 2 % ( v/v)乙醇之MEM培養基。連續將放置3天之含 有新鮮之各試料,或未含有之培養基相互交替進行培養8 天。此等依常法進行茜素紅- S染色法,測定鈣沈著量。 亦即,由培養感光板去除培養基後,以1 m 1 之 Dulbecco -磷酸緩衝生理食鹽水進行洗淨2次,添加1 ml之5 0 (v/v) %乙醇水溶液後,於室溫下放置 1 0分鐘。去除所添加之5 0 (v/v) %乙醇水溶液後 ,添加1 m 1蒸餾水後,再於室溫下放置1 〇分鐘。去除 所添加之蒸餾水後,添加1 m 1之1 % ( w / v )茜素紅 -S (和光純藥工業股份公司販賣)溶液後,放置1 〇分鐘之 後’去除茜素紅- S溶液後’以1 m 1蒸簡水進行洗淨3 次。藉由上記處理後,沈著鈣於培養感光板底面被染成紅 色,以肉眼判定鈣沈著量之紅色化程度。判定基準爲+ : 本紙張尺度適用中國國家標準(CNS ) A4規格(210 X 297公釐) -31 - 1331032 B7 五、發明説明(29 ) (請先閲讀背面之注意事項再填寫本頁) 與陰性對照(含〇 · 2% (v/v)乙醇之培養基)同程 度之染色,+ + + :與陽性對照(消炎痛)同程度之染色 ’++:陽光對照染色之5成左右之染色程度者。結果如 表9所示。 表9 有機化合物 鈣沈著量 0 · 2% (v/v)乙醇 + (陰性對照) 消炎痛 + + + 山萘黃素 + + + 桔皮素 + + + 没食子酸 + 咖啡酸 + 經濟部智慧財產局員工消費合作社印製 由表9之結果判定山萘黃素與桔皮素與做爲陽性對照 所採用之消炎痛呈幾乎相同之鈣沈著量者。此結果證明山 萘黃素與梧皮素具有增強前骨’芽細胞之錦沈著之作用。 由實驗1及2之結果判定山萘黃素係使前骨芽細胞之 鹼磷酸酶活性增加作用,亦即,具有使前骨芽細胞於骨芽 細胞進行分化之作用’且,證明山萘黃素、桔皮素均具有 增強鈣沈著之作用者。 〔實驗3〕各種類黃酮下之比較 本纸張尺度適用中.國國家標準(CNS ) A4規格(210X297公釐) -32- 1331032 A7 _B7__ 五、發明説明(30 ) 針對山萘黃素、桔皮素以外之類黃酮所屬化合物進行 檢測是否亦具相同效果。以黃酮(關東化學股份公司販賣 )’序黃素(funacoshi股份公司販賣),黃酮類(東京化成 工業股份公司販賣),槲皮黃素(關東化學股份公司販賣 )、山萘黃素(funacoshi股份公司販賣)、芸香苷(關東 化學股份販賣)、黃烷酮(關東化學股份公司販賣)、柚 符配基(Aldolichi販賣),梧皮素(funacoshi股份公司販 賣),桔皮苷(關東化學股份公司販賣),芳基丙烯醯芳烴 (melk公司販賣),根皮素(sigma公司販賣),兒茶酸 (sigma公司販賣),ipriflavone ( dait股份公司販賣), 黃杉素(f u n a c 〇 s h i股份公司販賣),硫擴菊素( funacoshi股份公司販賣),花青素(funacoshi股份公司販賣 ),做爲被驗試料採用之。以實驗1之方法進行測定鹼磷酸 酶活性。另外,鈣沈著量之測定係利用鈣C test和光(和光 純藥公司製)依常法進行之。亦即,由培養細胞去除培養基 後,以lml之Dulbecco—磷酸緩衝生理食鹽水進行洗淨 3次後,爲溶解沈著鈣而添加0.5ml之2N鹽酸。由 此溶解液採取5/zl後,添加0 · 5ml之0 · 88M單 乙醇胺緩衝液(ρ Η 1 1 ) ,0 .〇5 m 1含6 9 m Μ 8 -喹啉酚之0 . 6 3mM鄰甲酚酞配位劑(形成鈣離子 與螯合複合物。)·混合之。將此測定5 7 0 n m之吸光 度後,與同波長測定標準鈣溶液之値比較後,算出感光板 1孔之鈣量。評定方法針對各試料中鹼磷酸酶活性及鈣沈 著量分別比較對於含0 . 2 % ( v / v )乙醇之培養基所 本紙張尺度適用中.國國家標準(CNS ) A4規格(2丨OX297公釐) -------?- (請先閲讀背面之注意事項再填寫本頁) 訂 經濟部智慧財產局員工消費合作社印製 -33- 1331032
A B7 五、發明説明(31 ) 添加之陰性對照鹼磷酸酶活性及鹼沈著鈣量之相對活性及 相對量下進行之。結果如表1 0所示。 表1 0 經濟部智慧財產局員工消費合作社印製 相對鹼磷酸酶活性(%) 相對鈣沈著量(%) 0.2%(v/v)乙醇 100 100 黃酮 103 158 芹黃素 128 247 黃酮類 139 295 槲皮黃素 120 118 山萘黃素 162 305 芸香苷 109 74 黃烷酮 109 3 11 柚苷配基 1 10 27 1 桔皮素 1 I 6 289 桔皮苷 107 118 芳基丙烯醯芳烴 105 104 根皮素 109 238 兒茶酸 118 247 iprifla vone 1 14 263 黃杉素 98 234 硫磺菊素 126 157 花青素 1 15 216 -------f 丨 (請先閱讀背面之注意事項再填寫本頁)
,1T 本紙張尺度適用中.國國家標準(CNS ) A4規格(210X297公釐) -34- 1331032 A7 _____B7 五、發明説明(32) (請先閲讀背面之注意事項再填寫本頁) 由表1 0結果確定本發明有效成份之類黃酮出現增加 鈣沈著量者。由此結果證明,黃酮類、黃酮醇類、黃烷酮 類、二氫黃酮醇類、花色素類、黃烷醇類、芳基丙烯醯芳 烴類或噢嗦類均共同具有使前骨芽細胞於骨芽細胞進行分 化,增強鈣沈著之作用效果著。 〔實驗4〕鹼磷酸酶活性增強中山萘黃素、桔皮素、或 ipriflavone之作用效果的比較
山萘黃素或桔皮素及已做爲骨質疏鬆治療藥之公知的 ipriflavone做爲被驗試料使用後,比較前骨芽細胞於骨芽細 胞被分化誘導作用之強度。將含各被驗試料之培養基中培 養曰數做成3天'6天及9天者,培養基中被驗試料濃度 做成5、1 0、20//M以外,依實驗1之方法爲基準進 行之。培養基之乙醇濃度其各被檢試料濃度爲5 ;zM時呈 0 . 0 5 % ( v / v ) ,10//M 時呈 〇 . 1%(V/V 經濟·部智慧財產局員工消費合作社印製 ),20#M時呈〇 · 2% (v/v)。以未含與此等乙 醇濃度相同培養基之被驗試料做爲對照,求取對於對照活 性之相對活性。其結果如圖1所示。 由圖1結果確定被驗試料爲山萘黃素時呈濃度2 0 // Μ下稍遲緩培養6天後明顯出現鹼磷酸酶活性之增強作 用,又,被驗試料結皮素雖比i p r i f 1 a ν ο n e之活性稍差,惟 ,培養3天即明顯出現鹼磷酸酶活性之增強。由此結果證 明山萘黃素與桔皮素之增強老鼠前骨芽細胞(MC 3 丁 3 - E 1 )之鹼磷酸酶活性之效果不輸給做爲骨質疏鬆劑之 本紙張尺度適用中.國國家標準(CNS ) A4規格(210X297公釐〉 -35- 1331032 A7 ________B7 五、發明説明(33 ) ipriflavone 效果著。 (請先閲讀背面之注意事項再填寫本頁) 〔實驗5〕增強鈣沈著中山萘黃素與ipriflavone作用效果 之比較 針對鈣沈著量增強作用進行山萘黃素與iPriflavone之 比較。被驗試料及被驗試料之添加方法與實驗4同法進行 。鈣沈著量之測定係利用鈣C Test和光(和光純藥公司 販賣)依常法進行之。亦即,由培養細胞去除培養基,以1 m 1之Du lb ecco ~磷酸緩衝生理食鹽水進行洗淨3次後, 爲溶解沈著鈣而進行添加〇 . 5 m 1之2 N鹽酸。由此溶 解液採取5/z 1後,添加〇 _ 5ml之〇 . 88M單乙醇 胺緩衝液(pHl 1) ,〇 . 〇5ml之含69mM 8 -喹啉醇之〇 . 6 3 m Μ鄰甲酚酞配位劑(形成鈣離子 與螯合複合物)進行混合之。此測定波長5 7 0 n m之吸 光度後’比較以同波長測定標準鈣溶液之値後,算出感光 板1孔之妈K。圖2顯不山萘黃素與ipriflavone之比較。 另外’圖中亦顯示以對照之乙醇進行處理者。 經濟部智慧財產局員工消費合作社印製 由圖2之結果顯示山萘黃素比ipi.ifiavone更具良好之 鈣沈著增強作用。 由實驗4及5顯示山萘黃素及桔皮素對於老鼠前骨芽 細胞與做爲先行抗骨質疏鬆劑公知之ipriflavone相同具提 昇鹼磷酸酶活性’及鈣沈著增強作用,具有增強含鈣組織 之作用者。 本紙張尺度適用中國國家標準(CNS ) A4規格(2丨ΟΧΜ7公釐) -36 - 1331032 A7 B7 五、發明説明(34) 〔實驗6〕耗沈著增強中山萘黃素與iprjfiav〇ne或桔皮素 與ipriflavone之倂用效果 (請先閲讀背面之注意事項再填寫本頁) 利用山萘黃素或桔皮素後,與異黃酮類之ipriflav〇ne 倂用後’進行檢測其鈣沈著之增強作用。該試料之調製方 法,細胞之培養方法除使含有各被驗試料之培養基培養日 數爲5天之外,依實驗1爲基準,該鈣測定方法依實驗3 及實驗5爲基準進行之。又’含各被驗試料之培養基所含 乙醇濃度做成相同者。做爲被驗試料者如圖3所示,山萘 頁素 5 、1 〇 μΜ、2 0 βΜ 單獨,ipi-iflavone 5 #M、l〇#M、20#M單獨,或山萘黃素同時分別倂 用 ipriflavone 5/zM、10//M、20//M 者,如圖 4 所 示’桔皮素 5//M、1〇μΜ、20#M 單獨,ipriflavone 10/zM、20//M單獨,或桔皮素同時與 ipriflavone 分別倂用 5//M、10//M、20/zM 者。 由圖3及圖4結果確定對於前骨芽細胞其山萘黃素及 桔皮素比倂用ipriflavone與單獨時均明顯出現鈣沈著之增 強’倂用後,更出現相乘之效果。 經濟部智慧財產局員工消費合作社印製 〔實驗7〕實驗鼠大腿骨及脛骨中鈣沈著增強效果 以6隻3週齡雌性wister系實驗鼠做成1群使用之》 各被驗試料,亦即,各1重量份之桔皮素(funac0Shi股份 公司販賣),槲皮黃素(股份公司東京化成販賣)、α -糖 基桔皮苷(商品名『a G桔皮苷Ρ』林原商事股份公司販 賣)、α —糖基芸香苷(商品名『aG芸香苷Ρ』林原商 本紙張尺度適用中.國國家榡準(CNS ) A4規格(210X297公釐) 1331032 A7 B7 五、發明説明(35) 事股份公司販賣)、ipriflavone ( dait股份公司販寶)( 陽性對照)摻合表1 1所示摻合比率之高蔗糖添加飼料( 表1 1中各數値以重量%示之),此做爲餌給與實驗鼠。 添加1重量份蔗糖之餌給與實驗鼠者取代被驗試料做爲對 照。水自由攝取之。試驗開始8週後,屠殺實驗鼠,摘取 大腿及脛骨。摘出之大腿骨及脛骨於1 〇 〇 °C下進行乾燥 約6小時後,以高精度分析用上皿電子天秤(商品名『 HA180M/12QM』,股份公司A&D販賣)進行 測其乾燥重量。再將大腿骨及脛骨置入坩堝中,於灰化爐 ’ 9 5 0 °C下進行處理6小時後,充份灰化後,溶於鹽酸 液後’此做成試料液後,以原子吸光光度計定量鈣量。鈣 量係算出1根乾燥骨之鈣量後,與對照進行比較者。結果 如表1 2所示。 (請先閲讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 本紙張尺度適用中.國國家標準(CNS ) A4規格(210X297公釐) -38- 1331032 A7 B7 五、發明説明(36 ) 表1 1 飼料成分 (重量%) 試驗群 無 (對照 群) 桔皮 素 槲皮 黃素 -糖基 芸香苷 α -糖基 洁皮普 iprif la vone 類黃酮類 (試料) 0.5 0.5 1.25 1.25 0.5 0 玉米澱粉 14.5 14.5 13.75 13.75 14.5 15 蔗糖 50 酪蛋白 20 纖維素粉末 5 玉米油 5 鑛物質類 3.5 維他命類 1.2 蛋胺酸 0.3 (請先閲讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 本纸張尺度適用中.國國家標準(CNS ) A4規格(210Χ297公釐) -39- 1331032 Α7 Β7 五、發明説明(37 ) 表12 試料 乾燥骨重量 (g ) 乾燥骨一根 之鈣重量 (mg) 考備 桔皮素 大腿骨 0.463 125.1 本發明 脛骨 0.357 109.0 槲皮黃素 大腿骨 0.456 120.3 本發明 脛骨 0.352 108.7 α -糖基芸 大腿骨 0.439 119.9 本發明 香甘 脛骨 0.343 107.7 α -糖基桔 大腿骨 0.454 126.9 本發明 皮苷 脛骨 0.349 109.5 ipriflavone 大腿骨 0.428 120.0 陽性對照 脛骨 0.338 106.0 Μ J » 大腿骨 0.427 116.4 陰性對照 脛骨 0.33 1 105.9 ih-----0ΐ (請先閲讀背面之注意事項再填寫本頁) 訂 經濟部智慧財產局員工消費合作社印製 由表1 2之結果顯示大腿骨及脛骨之鈣沈著量其任意 各被驗試料比陰性對照均較增強,與陽性對照之ipriflavone 同等或同等以上者。另外,桔皮苷、α_糖基桔皮苷、及 α -糖基芸香苷之配糖體中亦出現鈣沈著量之增加。又, 利用此等配糖體進行檢測體外之鹼磷酸酶活性及鈣沈著增 強作用後,未出現有意義之增強作用。因此,發揮此效果 其各類黃酮務必呈配基。之形態者、生體內投與時,藉由 本紙張尺度適用中周國家標準(CNs ) a4規格(210 X 297公釐) -40- 1331032 A7 ____B7_ 五、發明説明(38 ) 腸管內或生體內之酵素後,其糖部份被分解,呈配基進行 作用之。 (請先聞讀背面之注意事項再填寫本頁) 〔實驗8〕急性毒性試驗 經濟部智慧財產局員工消費合作社印製 使用1群5隻4週齡wist er系雌性實驗鼠。以實驗3 所使用之各有機化合物做爲被驗試料,亦即,將各1重量 份之黃酮(關東化學股份公司販賣),芹黃素(funacoshi 股份公司販賣),黃酮醇(東京化成工業股份公司販賣), 槲皮黃素(關東化學股份公司販賣)、山萘黃素(funacosh i股份公司販賣)、芸香苷(關東化學股份公司販賣)、黃 烷酮(關東化學股份公司販賣)、柚苷配基(Aldolichi 販賣),桔皮素(funacoshi股份公司販賣),桔皮苷(關東 化學股份公司販賣),芳基丙烯醯芳烴(melk公司販賣 ),根皮素(sigma公司販賣),兒茶酸(sigma公司販賣 ),ipriflavone ( dait 股份公司販賣),黃杉素(funacoshi 股份公司販賣),硫磺菊素(funacoshi股份公司販賣),或 花青素(funacoshi股份公司販賣)於2 5重量份之5 ( w/ v ) %阿拉伯膠溶液中進行溶解或懸浮後,於絕食 1 8小時之實驗鼠中利用胃探針以1 〇 m 1 / k g實驗鼠 體重之用量強制進行經口投服。之後,實驗鼠於恆溫恒濕 之條件下進行飼養’任其自由攝取餌及水。以0日做爲投 服日進行各個體之體重測定,同時進行1 4天一般症狀及 存活情況。 2週飼養後’任意被驗試料中均無死亡例,且,體重 本紙張尺度適用中.國國家標準(CNS ) A4規格(210X297公釐) -41 - 1331032 A7 _________B7_ 五、發明説明(39) (請先閲讀背面之注意事項再填寫本頁} 亦未減輕,外觀呈良好者,亦未出現較明顯之一般症狀。 因此’判定本發明增強含鈣組織用劑做爲有效成份使用之 一般式1至5物質具有極高之安全性者。 以下,說明本發明實施例。 〔實施例1〕液劑 將1重量份之α -糖基芸香素(商品名『ccG芸香素 P』股份公司林原商事販賣)及0 · 1重量份之槲皮黃素 (funacoshi股份公司販賣)溶於5 0重量份之乙醇後’更加 入5,000重量份之水,50重量份之α,〇: -海藻糖 (商品名『treha』股份公司林原商事販賣),3重量份乳 酸鈣,1 . 5重量份氯化鎂,及10重量份酪蛋白磷胜肽 後,進行混合溶解之後,取得液狀之增強含鈣組織用劑。 可方便服用,被摻合於具吸收效率良好之鈣的本品因 可有效維持,增強含鈣組織,可有效利用於骨質疏鬆症, 骨折等治療、預防或促進恢復等。 經濟部智慧財產局員工消費合作社印製 〔實施例2〕液劑 將1重量份之α -糖基桔皮苷(商品名『a G桔皮苷 ΡΑ』股份公司林原商事販賣)及0 . 1重量份之桔皮素 (funacoshi股份公司販賣)溶於5 〇重量份乙醇後,更添加 5,000重量份之水,20重量份之αα —海藻糖( 商品名『treha』股份公司林原商事販賣)、5重量份之氯 化鈣、2 . 5重量份之氯化鎂、及1 〇重量份之乳蔗糖後 -42- 本纸張尺度適用中.國國家標準(CNS ) A4規格(210 X297公釐) 1331032 A7 B7 五、發明説明(40 ) ,進行混合溶解後,取得液狀之增強含鈣組織用劑。 <請先閲讀背面之注意事項再填寫本頁) 可方便服用,摻合具良好吸收效率鈣之本品可有效維 持,增強含鈣組織,因此,可有效利用於骨質疏鬆症、骨 折等之治療,預防或促進恢復等者。 〔實施例3〕液劑 將6重量份之氯化鈉,0 · 3重量份之氯化鉀、 0 . 2重量份之氯化鈣,3 . 1重量份之乳酸鈉、45重 量份之α,Θ -海藻糖,以及1重量份之特開平5 — 3 2 6 9 0公報實施例Α - 2方法所取得之粉末狀α -糖 基槲皮黃素溶於1, 0 0 0重量份之水後,依常法,精製 過濾後做成無熱原者,此溶液經滅菌後塡入2 5 m 1安瓶 後取得注射用之增強含鈣組織用劑。 本品做爲注射劑可有效維持,增強鈣組織之效果,因 此可有效利用骨質疏鬆症、骨折等之治療、預防或恢復的 促進等。 經濟部智慧財產局員工消費合作社印製 〔實施例4〕粉劑 均勻混合1重量份之α -糖基芸香苷(商品名『aG 芸香苷Η』股份公司林原商事販賣),5重量份之大豆異 黃酮(不二製油股份公司販賣)、1 〇 〇 〇重量份之〇:, α -海藻糖粉末(商品名『treha』股份公司林原商事販賣 ),1重量份之乳酸鈣,0 · 5重量份之硫酸鎂後,進行 乾燥後,製造粉末狀之增強含鈣組織用劑。 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) -43 - 經濟部智慧財產局員工消費合作社印製 1331032 A7 _______B7___ 五、發明説明(41 ) 安定之本品易溶於水,亦含有鈣及鎂,因此,具有良 好強化含鈣組織之效果者,做爲骨質疏鬆症、骨折等之治 療 '預防之增強含鈣組織用劑、或做爲健康補助食品,保 健機能食品等之健康食品者爲極有用者。 〔實施例5〕粉劑 均勻混合1重量份之α -糖基桔皮苷(商品名.『a G 桔皮苷Η』股份公司林原商事販賣),1000重量份之 α,α —海藻糖粉末(商品名『treha』股份公司林原商事 販賣)、1重量份之乳酸鈣,0 . 5重量份之硫酸鎂,3 重量份之L 一抗壞血酸一 2 -糖苷(商品名『AA2G』 股份公司林原商事販賣)後,進行乾燥之後,製造粉末狀 之增強含鈣組織用劑。 安定之本品,易溶於水,亦含有鈣及鎂,因此,具有 良好增強含鈣組織之效果。做爲骨質疏鬆症、骨折等治療 ,預防之增強含鈣組織用劑,或做爲健康補助食品,保健 機能食品等健康食品爲有用者。 〔實施例6〕含錠劑 將1重量份之α -糖基桔皮苷(商品名『aG桔皮苷 PA』股份公司林原商事販賣)'及0.1重量份之桔皮 素(funacoshi股份公司販賣)溶於1重量份之乙醇後,充份 混合.2重量份之乳酸鈣,1 0重量份之阿拉伯膠,1 〇重 量份之α,α —海藻糖粉末(商品名『treha』股份公司林 本纸張尺度適用中.國國家標準(CNS ) A4規格(210X29*7公釐) ~ -44 - (請先閲讀背面之注意事項再填寫本頁)
1331032 A7 B7 五、發明説明(42) 原商事販賣),5重量份蔗糖(三榮源F · F · I股份公 (請先閲讀背面之注意事項再填寫本頁) 司販賣)、3重量份之水後,依常法進行成型後,取得含 錠劑。 安定之本品可做爲維持,增強齒槽骨及齒鈣量之含錠 劑爲有用者。 〔實施例7〕含錠劑 將1重量份之糖基芸香苷(商品名『ctG芸香苷 P』B份公司林原商事販賣)、及〇·1重量份之槲皮黃 素(f u n a c 〇 s h i股份公司販賣)溶於1重量份之乙醇後,加入 2重量份之乳酸鈣,1〇重量份之阿拉伯膠,1〇重量份 之α,α-海藻糖粉末(商品名『treha』股份公司林原商 事販賣),2重量份之糖轉移stevia,3重量份之水充份混 合後,依常法進行成型後,取得含錠劑。 安定之本品可有效做爲維持,增強齒槽骨及齒鈣量之 含錠劑之用者。 經濟部智慧財產局員工消費合作社印製 〔實施例8〕健康補助食品 將5 2重量份之α,α —海藻糖粉末(商品名『treha 』股份公司林原商事販賣)、4 0重量份之玉米澱粉、 0 · 5重量份之α -糖基芸香苷(商品名『aG芸香苷P 』股份公司林原商事販賣)、0 . 5重量份之α-糖基桔 皮苷.(商品名『a G桔皮苷P A』股份公司林原商事販賣 )、0 · 1重量份之L —抗壞血酸—2 —糖苷(商品名『 本&張尺度適用中國國家標準(CNS ) A4规格(2丨0X297公釐) -45 - 1331032 五、發明説明(43 AA2 G』股份公司林原商事販賣)氯化鈣,以及2 . 5 重量份之結晶纖維素進行混合後,依常法進行噴霧滴入適 量水之同時進行混煉後,流動層造粒之後,進行粉碎,整 粒之後取得打錠用粉狀物。此加入做爲潤滑劑之2重量份 蔴糖脂肪酸酯均勻混合之,藉由裝有直徑1 1mm杵之打 旋機進行打錠後取得錠劑(約3 〇 〇 m g /錠)。 易於攝取,於消化管中具良好崩散性之本品可有效做 爲維持,增強骨量之健康補助食品,保健機能食品等健康 食品之用。 〔實施例9〕飲料劑 將1重量份之α -糖基芸香苷(商品名『aG芸香苷 P』股份公司林原商事販賣),1重量份載於特開平4_ 1 3 6 9 1號公報實施例a- 2之方法所製造之α —糖基 柚普’ 2 0重量份葡萄柚果汁,2重量份之α,α -海藻 糖粉末(商品名『treha』股份公司林原商事販賣),2重 量份檸檬酸,1重量份L_抗壞血酸- 2 -糖苷(商品名 股份公司林原商事販賣)、5重量份異構化 糖’ 6重量份海水、2重量份氯化鈣、及1 6 0重量份之 水進行混合後各塡入i 〇 〇 m 1於玻璃瓶中,進行密栓後 ’取得飮料劑。 本品,不但風味佳,更具增強含鈣組織之作用,因此 ’可有效做爲骨質疏鬆症、骨折等之治療、預防的飮料劑 之用者。 本紙張尺度適用中國國家標準(CNS ) M規格(210X297公釐) -------f 丨 (請先聞讀背面之注意事項再填寫本頁) 訂 經濟部智慧財產局員工消費合作社印製 46- 1331032 經濟部智慧財產局員工消費合作社印製 A7 B7 五、發明説明(44 ) 〔實施例1 0〕飮料劑 混合1重量份之α -糖基梧皮苔(簡品名^ a G桔皮有: ΡΑ』股份公司林原商事販賣)、5 0重量份蘋果汁,5 重量份異構化糖,2重量份L 一抗壞血酸,3重量份a, α -海藻糖(商品名『treha』股份公司林原商事販賣)、 2重量份L —天冬胺酸鈉,3 5重量份之水後,分別以 1 0 0 m 1塡入玻璃瓶中,進行密栓後,取得飮料劑^ 本品具良好風味,且具增強含鈣組織之作用,因此, 可有效做爲骨質疏鬆症、骨折等之治療,預防之飮料劑之 用者。 〔實施例1 1〕糊劑 依常法於4 5重量份之磷酸氫鈣,3重量份之支鏈激 粉,1 . 5重量份之月桂硫酸鈉,20重量份之甘油, 0 · 5重量份之聚環氧乙烷山梨糖醇酐月桂酸酯,1〇重 量份之山梨糖醇,7重量份之多糖.醇,12重量份之精製 水中摻合0 · 4重量份之α -糖基桔皮苷(商品名『α(3 桔皮苷PA』股份公司林原商事販賣),及含有〇 . 1重 量份之桔皮素(funacoshi股份公司販賣)之1重量份乙醇溶 液後,取得糊劑。 安定之本品可有效做爲維持,增強齒槽骨及齒鈣量之 牙膏之用。 〔實施例1 2〕糊劑 本纸張尺度適用中.國國家標準(CNS ) A4㈣ ( 21GX 297公楚) ~ -47- --------f (請先閲讀背面之注意事項再填寫本1)
*1T 1331032 A7 B7 五、發明説明(45 ) 依常法於4 5重量份之磷酸氫鈣,3重量份之支鏈澱 粉’ 1 · 5重量份之月桂硫酸鈉,2 0重量份之甘油, (請先聞讀背面之注意事項再填寫本頁) 〇 · 5重量份之聚環氧乙烯山梨糖醇酐月桂酸酯,10重 量份之山梨糖醇,7重量份之多糖醇及1 2重量份之精製 水中摻合0 · 4重量份α -糖基芸香苷(商品名『ctG芸 香有:P』股份公司林原商事販賣),及含0 . 1重量份之 槲皮黃素(funacoshi股份公司販賣)之1重量份乙醇溶液後 取得牙膏。 安定之本品可有效做爲維持,增強齒槽骨及齒鈣量之 牙膏之用者。 〔產業上可利用性〕 經濟部智慧財產局員工消費合作社印製 —般式1至5物質或含其前驅物之增強含鈣組織用劑 於前骨芽細胞或骨芽細胞中顯示強力鈣沈著活性,更且, 其作用藉由添加異黃酮類之後,明顯出現相乘增強效果, 因此,具滑成長及骨形成促進效果及骨量增加之效果,不 僅可攝取於含於健康補助食品,保健機能食品等之健康食 品者,即使做爲日常飮食品.亦無不妥感可輕易攝取之。本發 明增強含鈣組織用劑特別可防止高齡者之骨、齒弱化,同 時亦可有效治療及預防骨質疏鬆症。更且,對低齡層因飮 食失調產生骨成長。骨形成延緩之預防亦有極高效困者。 本纸張尺度適用中.國國家標準(CNS ) A4規格(210X297公釐) -48-
Claims (1)
1331032 A8 B8 C8 D8 申請專利範圍 第9 1 1 09304號專利申請案 (Π卑《月〕1 中文申請專利範圍修正本 民國99年6月7日修正 1 · 一種增強含鈣組織用劑,其特徵係含有1種或2種 以上選自芹黃素、黃酮醇、山萘黃素、槲皮黃素、黃烷酮 、柚苷配基、桔皮素、花青素、兒茶酸及硫磺菊素作爲有 效成分者。 2 ·如申請專利範圍第1項之增強含鈣組織用劑,其更 含有異黃酮類做爲有效成份者。 3 ·如申請專利範圍第2項之增強含鈣組織用劑,其中 該異黃酮類爲異丙黃酮或大豆異黃酮者。 4 ·如申請專利範圍第2項或第3項之增強含鈣組織用 劑’其中該異黃酮類爲配醣基,配糖體,聚合物及/或衍生 物者。 5 .如申請專利範圍第1項或第2項之增強含鈣組織用 劑’其中該劑更含有1種或2種以上選自礦物質、具有礦 物質吸收促進作用之物質,低聚糖及維他命者。 經濟部智慧財產局員工消費合作社印製 ~w # £ (請先閱脅背面之注意事項再填寫本頁) 6 .如申請專利範圍第5項之增強含鈣組織用劑,其中 該礦物質爲鈣化合物及/或鎂化合物者。 7 .如申請專利範圍第5項之增強含鈣組織用劑,其中 該具有礦物質吸收促進作用之物質爲酪蛋白磷胜肽及/或低 聚糖者。 8 .如申請專利範圍第5項之增強含鈣組織用劑,其中 該低聚糖爲左旋低聚糖、異麥芽低聚糖、木質低聚糖、乳 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 1331032 A8 B8 C8 D8 六、申請專利範圍2 蔗糖、大豆低聚糖、α,α-海藻糖及/或α ; /3·海藻糖者 〇 9 .如申請專利範圍第5項之增強含鈣組織用劑,其中 該維他命爲維他命D、維他命K、L-抗壞血酸及/或其衍生 物者。 I 0 · —種飮食品,其特徵係摻合如申請專利範圍第1 項至第9項中任一項之增強含鈣組織用劑所成者。 II ·如申請專利範圍第1 〇項之飮食品,其中該飮食品 爲健康食品。 :----^-- (請先閲讀背面之注意事項再填寫本頁) -3 線 經濟部智慧財產局員工消費合作社印製 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) -2-
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002130154A JP4390428B2 (ja) | 2001-05-01 | 2002-05-01 | 含カルシウム組織強化剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
TWI331032B true TWI331032B (zh) | 2010-10-01 |
Family
ID=29397322
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW091109304A TWI331032B (zh) | 2002-05-01 | 2002-05-02 |
Country Status (5)
Country | Link |
---|---|
US (2) | US20050215493A1 (zh) |
EP (1) | EP1514540B1 (zh) |
KR (1) | KR100946822B1 (zh) |
TW (1) | TWI331032B (zh) |
WO (1) | WO2003092666A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9308222B2 (en) | 2008-01-28 | 2016-04-12 | Yun Kau Tam | Formulas comprising highly soluble elements and vitamins for the prevention and amelioration of osteoporosis |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1643863A2 (en) * | 2003-07-10 | 2006-04-12 | Carl A. Forest | Foods, beverages, condiments, spices and salad dressings with specialized supplements |
RU2431634C2 (ru) * | 2005-03-11 | 2011-10-20 | Говард Флори Инститьют Оф Експериментл Физиолоджи Энд Медсин | Соединения флавоноидов и их применение |
EP2368442B1 (en) | 2005-07-27 | 2014-12-17 | Symrise AG | Use of hesperetin for enhancing the sweet taste |
US20070092454A1 (en) * | 2005-10-24 | 2007-04-26 | Colgate-Palmolive Company | Oral composition containing morin |
US9101160B2 (en) | 2005-11-23 | 2015-08-11 | The Coca-Cola Company | Condiments with high-potency sweetener |
US20070116836A1 (en) * | 2005-11-23 | 2007-05-24 | The Coca-Cola Company | High-Potency Sweetener Composition for Treatment and/or Prevention of Osteoporosis and Compositions Sweetened Therewith |
US20070269541A1 (en) * | 2006-05-19 | 2007-11-22 | Peter Rohdewald | Method and compositions for relieving menopausal and perimenopausal symptoms |
US20080003300A1 (en) * | 2006-06-30 | 2008-01-03 | Gaffar Maria C | Compostions containing Mg/Zn/F-CaP plus inhibitors of pro-inflammatory Cytokines (a combination of a Free-B-Ring flavonoids and a flavan) for osteoporosis prevention, therapy and treatment of bone diseases |
GB0614353D0 (en) | 2006-07-20 | 2006-08-30 | Oraldent Ltd | Oral compositions, their preparation and use |
KR101471215B1 (ko) * | 2006-10-24 | 2014-12-09 | 크렘핀, 로리에 | 항-재흡수 및 골 형성 식이보충제 및 이의 사용 방법 |
US8017168B2 (en) | 2006-11-02 | 2011-09-13 | The Coca-Cola Company | High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith |
JP5374491B2 (ja) * | 2007-04-02 | 2013-12-25 | アビラ,アルフレド | 骨折および骨欠損の処置のためのハーブ製剤 |
KR20100126462A (ko) * | 2008-03-05 | 2010-12-01 | 카운실 오브 사이언티픽 엔드 인더스트리얼 리서치 | 신규한 플라보놀 화합물로서, 골건강 관련 질환을 치료 또는 예방하기 위한 울무스 왈리치아나로부터의 생활성 추출물/분획 및 그의 화합물 |
AU2011261225B2 (en) * | 2010-06-03 | 2014-12-11 | Stokely-Van Camp, Inc. | Electrolyte blends providing reduced salty taste |
CN103096737A (zh) | 2010-09-17 | 2013-05-08 | 斯托克里-丰康普公司 | 减少血液乳酸盐浓度的方法 |
CN103211836A (zh) * | 2013-04-11 | 2013-07-24 | 天津天狮生物发展有限公司 | 一种治疗骨质疏松的组合物 |
WO2019059275A1 (ja) | 2017-09-21 | 2019-03-28 | 学校法人北陸大学 | 骨のリモデリング促進剤 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0629182B2 (ja) * | 1986-12-20 | 1994-04-20 | キツセイ薬品工業株式会社 | 骨粗鬆症治療剤 |
JPH0629183B2 (ja) * | 1986-12-22 | 1994-04-20 | キツセイ薬品工業株式会社 | 骨粗鬆症治療剤 |
JPH0629185B2 (ja) * | 1986-12-22 | 1994-04-20 | キツセイ薬品工業株式会社 | 骨粗鬆症治療剤 |
JPH0629184B2 (ja) * | 1986-12-22 | 1994-04-20 | キツセイ薬品工業株式会社 | 骨粗鬆症治療剤 |
JPH0729921B2 (ja) * | 1987-02-14 | 1995-04-05 | キツセイ薬品工業株式会社 | 骨粗鬆症治療剤 |
JPH0729920B2 (ja) * | 1987-02-14 | 1995-04-05 | キツセイ薬品工業株式会社 | 骨粗鬆症治療剤 |
JP3060227B2 (ja) * | 1989-06-03 | 2000-07-10 | 株式会社林原生物化学研究所 | α―グリコシル ヘスペリジンとその製造方法並びに用途 |
US5478579A (en) * | 1991-02-06 | 1995-12-26 | Biodyn Medical Research, Inc. | Method for treatment of osteoporosis |
EP0619116A3 (en) * | 1993-04-05 | 1994-11-23 | Hoechst Japan | Use of synthetic retinoids for osteopathy. |
US6261565B1 (en) * | 1996-03-13 | 2001-07-17 | Archer Daniels Midland Company | Method of preparing and using isoflavones |
US6297273B1 (en) * | 1996-04-02 | 2001-10-02 | Mars, Inc. | Use of cocoa solids having high cocoa polyphenol content in tabletting compositions and capsule filling compositions |
AU6765798A (en) * | 1997-03-20 | 1998-10-12 | Coventry Group, Ltd. | Nutritional supplement for cardiovascular health |
JP3250071B2 (ja) * | 1997-06-26 | 2002-01-28 | 株式会社ホーネンコーポレーション | 抗骨粗鬆症組成物 |
EP1656942A3 (en) * | 1997-08-08 | 2008-02-27 | Otsuka Pharmaceutical Co., Ltd. | Isoflavone-containing composition |
WO1999007381A1 (en) * | 1997-08-11 | 1999-02-18 | Weider Nutrition International, Inc. | Compositions and treatments to reduce side effects of administration of androgenic testosterone precursors |
AU4573899A (en) * | 1998-06-19 | 2000-01-05 | Beth Israel Deaconess Medical Center | Dietary supplement for post-menopausal women |
ID28460A (id) * | 1998-07-08 | 2001-05-24 | Lipogenics Inc | Komposisi dan metoda untuk perlakuan dan pencegahan penyakit tulang dengan menggunakan tocotrienol |
JP3010210B1 (ja) * | 1998-09-02 | 2000-02-21 | 農林水産省果樹試験場長 | マトリックスメタロプロテアーゼ産生阻害剤 |
WO2000067749A1 (en) * | 1999-05-05 | 2000-11-16 | Unilever N.V. | Food product |
WO2001015553A1 (en) * | 1999-08-27 | 2001-03-08 | Michigan State University | Dietary food supplement containing natural cyclooxygenase inhibitors |
JP2001072582A (ja) * | 1999-09-07 | 2001-03-21 | Sunstar Inc | 機能性経口組成物 |
JP2001114675A (ja) * | 1999-10-12 | 2001-04-24 | Fancl Corp | ビタミン組成物 |
EP1127572A3 (en) * | 2000-02-25 | 2003-05-02 | Basf Aktiengesellschaft | Use of flavones for treating cycloxygenase-2 mediated diseases |
DE60120691T2 (de) * | 2000-06-02 | 2007-06-06 | Merck Patent Gmbh | Zusammensetzungen zur verwendung bei der behandlung der osteoporose und/oder der entzündlichen gelenkerkrankungen |
-
2002
- 2002-05-02 KR KR1020047017557A patent/KR100946822B1/ko active IP Right Grant
- 2002-05-02 EP EP02807341.9A patent/EP1514540B1/en not_active Expired - Lifetime
- 2002-05-02 US US10/513,119 patent/US20050215493A1/en not_active Abandoned
- 2002-05-02 WO PCT/JP2002/004407 patent/WO2003092666A1/ja active Application Filing
- 2002-05-02 TW TW091109304A patent/TWI331032B/zh not_active IP Right Cessation
-
2008
- 2008-09-15 US US12/210,587 patent/US8778882B2/en not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9308222B2 (en) | 2008-01-28 | 2016-04-12 | Yun Kau Tam | Formulas comprising highly soluble elements and vitamins for the prevention and amelioration of osteoporosis |
Also Published As
Publication number | Publication date |
---|---|
US8778882B2 (en) | 2014-07-15 |
EP1514540B1 (en) | 2014-08-27 |
KR100946822B1 (ko) | 2010-03-09 |
WO2003092666A1 (fr) | 2003-11-13 |
EP1514540A4 (en) | 2006-03-08 |
KR20040101576A (ko) | 2004-12-02 |
EP1514540A1 (en) | 2005-03-16 |
US20090075908A1 (en) | 2009-03-19 |
US20050215493A1 (en) | 2005-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI331032B (zh) | ||
JP7054242B2 (ja) | 毛乳頭細胞賦活促進剤、及びvegf産生促進剤 | |
ES2247858T3 (es) | Tratamiento del cancer de mama mediante el uso de aceites esenciales de plantas. | |
CN102264222B (zh) | 抗病毒补剂 | |
JPH11302142A (ja) | 歯周病の予防又は治療用の食品組成物、口腔用組成物及び医薬組成物 | |
CZ336899A3 (cs) | Antimikrobiální prevence a léčba lidského viru imunodeficience a dalších infekčních onemocnění | |
HU228847B1 (en) | Insulin preparations, which do not contain any zinc or only a small quantity of zinc and which have an improved stability | |
WO2020262325A1 (ja) | 雌の抗老化剤 | |
JP6370302B2 (ja) | γ−シクロデキストリンを含むカテキン生体利用率増進剤とカテキンとを含む組成物 | |
JP4390428B2 (ja) | 含カルシウム組織強化剤 | |
TW542829B (en) | Acyl derivatives of glycosyl-L-ascorbic acid | |
WO1999044440A1 (fr) | Compositions alimentaires pour prevenir la parodontose ou la progression de la parodontose et methode de prevention et de traitement de la parodontose | |
TW200402301A (en) | Treatment of mucositis | |
JP4515556B2 (ja) | 脂肪蓄積抑制剤、抗肥満剤、食品添加物、食品及びペットフード | |
US6077872A (en) | Use of calcium L-threonate in preventing, inhibiting and curing osteoporosis and rickets | |
WO2016018055A1 (ko) | 톳 추출물을 포함하는 치주질환 치료용 조성물 | |
JP5523663B2 (ja) | 歯根−歯周組織形成促進用医薬組成物 | |
KR102040809B1 (ko) | 홍합패각 및 올리고당을 유효성분으로 함유하는 칼슘복합제 및 이의 용도 | |
CN107427488A (zh) | 鞣花酸二水合物在食品和保健品中的用途 | |
CN113712982B (zh) | 一种预防或治疗非酒精性脂肪肝、肥胖症的组合物及制备方法和应用 | |
KR102225792B1 (ko) | 에키노크롬 a를 유효성분으로 함유하는 폐경기 증후군의 치료 또는 예방용 약학적 조성물 | |
KR20220132935A (ko) | 고용량의 비타민 c를 함유하는 조성물의 비만 및 비알코올성 지방간 질환의 예방, 개선 또는 치료 용도 | |
US20110003891A1 (en) | Novel use of zinc n-acetyltaurinate | |
Krasner et al. | Alcohol and absorption from the small intestine. 2. Effect of ethanol on ATP and ATPase activities in guinea-pig jejunum. | |
KR20040018335A (ko) | 성 기능 장애의 예방 및 치료에 유용한 약제의 제조에서n-아세틸-d-글루코사민의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK4A | Expiration of patent term of an invention patent |